Merrimack Pharmaceuticals, Inc. MACK NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

54/100

2/5 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Merrimack Pharmaceuticals, Inc. (MACK) .

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分： 51/100 其中 2/7 项标准通过。

SharesGrow 7-Criteria Score

54/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

未來

40/100

Analyst consensus

→ Forecast

✗

过去

0/100

→ Income

✓

健康

100/100

Debt-to-Equity & liquidity

→ Health

✗

护城河

28/100

→ Income

✓

成长

100/100

→ Income

—

收入

N/A

No coverage

估值概览 — MACK

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率0.00

EV/EBITDA0.0

每股数据

EPS (TTM)$-0.08

每股账面价值$0.00

每股营收$0.00

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2014	$-7.98	$102.76M	$-83.29M	-81.1%
2015	$-13.29	$89.26M	$-147.96M	-165.8%
2016	$-12.11	$144.27M	$-151.74M	-105.2%
2017	$35.67	$0.00	$472.03M	-
2018	$-3.04	$0.00	$-40.51M	-
2019	$-1.59	$0.00	$-21.27M	-
2020	$-0.23	$0.00	$-3.03M	-
2021	$-0.18	$0.00	$-2.46M	-
2022	$-0.11	$0.00	$-1.54M	-
2023	$-0.08	$0.00	$-1.18M	-